These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23547084)

  • 1. Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147.
    Phipps AI; Shi Q; Newcomb PA; Nelson GD; Sargent DJ; Alberts SR; Limburg PJ
    J Clin Oncol; 2013 Jun; 31(16):2016-23. PubMed ID: 23547084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
    Yoon HH; Tougeron D; Shi Q; Alberts SR; Mahoney MR; Nelson GD; Nair SG; Thibodeau SN; Goldberg RM; Sargent DJ; Sinicrope FA;
    Clin Cancer Res; 2014 Jun; 20(11):3033-43. PubMed ID: 24687927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR
    J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
    JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.
    Alberts SR; Sargent DJ; Nair S; Mahoney MR; Mooney M; Thibodeau SN; Smyrk TC; Sinicrope FA; Chan E; Gill S; Kahlenberg MS; Shields AF; Quesenberry JT; Webb TA; Farr GH; Pockaj BA; Grothey A; Goldberg RM
    JAMA; 2012 Apr; 307(13):1383-93. PubMed ID: 22474202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
    Taieb J; Balogoun R; Le Malicot K; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Emile JF; Mulot C; Fratté S; Levaché CB; Saban-Roche L; Thaler J; Petersen LN; Bridgewater J; Perkins G; Lepage C; Van Cutsem E; Zaanan A; Laurent-Puig P;
    Ann Oncol; 2017 Apr; 28(4):824-830. PubMed ID: 28031175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
    Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
    Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
    Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
    Blons H; Emile JF; Le Malicot K; Julié C; Zaanan A; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Nørgård-Petersen L; Van Cutsem E; Lepage C; Zawadi MA; Salazar R; Laurent-Puig P; Taieb J
    Ann Oncol; 2014 Dec; 25(12):2378-2385. PubMed ID: 25294886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
    Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.
    Huang J; Nair SG; Mahoney MR; Nelson GD; Shields AF; Chan E; Goldberg RM; Gill S; Kahlenberg MS; Quesenberry JT; Thibodeau SN; Smyrk TC; Grothey A; Sinicrope FA; Webb TA; Farr GH; Pockaj BA; Berenberg JL; Mooney M; Sargent DJ; Alberts SR;
    Clin Colorectal Cancer; 2014 Jun; 13(2):100-9. PubMed ID: 24512953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
    Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
    BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
    Ogino S; Liao X; Imamura Y; Yamauchi M; McCleary NJ; Ng K; Niedzwiecki D; Saltz LB; Mayer RJ; Whittom R; Hantel A; Benson AB; Mowat RB; Spiegelman D; Goldberg RM; Bertagnolli MM; Meyerhardt JA; Fuchs CS;
    J Natl Cancer Inst; 2013 Dec; 105(23):1789-98. PubMed ID: 24231454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
    Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
    JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.
    Yoon HH; Shi Q; Alberts SR; Goldberg RM; Thibodeau SN; Sargent DJ; Sinicrope FA;
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26160882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
    Ogino S; Shima K; Meyerhardt JA; McCleary NJ; Ng K; Hollis D; Saltz LB; Mayer RJ; Schaefer P; Whittom R; Hantel A; Benson AB; Spiegelman D; Goldberg RM; Bertagnolli MM; Fuchs CS
    Clin Cancer Res; 2012 Feb; 18(3):890-900. PubMed ID: 22147942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
    JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.
    Ng K; Ogino S; Meyerhardt JA; Chan JA; Chan AT; Niedzwiecki D; Hollis D; Saltz LB; Mayer RJ; Benson AB; Schaefer PL; Whittom R; Hantel A; Goldberg RM; Bertagnolli MM; Venook AP; Fuchs CS
    J Natl Cancer Inst; 2011 Oct; 103(20):1540-51. PubMed ID: 21849660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.